AI Engines For more Details: Perplexity Kagi Labs You
Seizure Control: Primidone is an anticonvulsant medication that is effective in controlling seizures. It is commonly used in the treatment of generalized tonic-clonic seizures (formerly known as grand mal seizures) and partial seizures (including complex partial seizures and simple partial seizures). Primidone helps reduce the frequency and severity of seizures by stabilizing electrical activity in the brain.
Essential Tremor: In addition to epilepsy, primidone may also be prescribed for the treatment of essential tremor, a neurological disorder characterized by involuntary shaking of the hands, head, or other parts of the body. Primidone can help reduce the severity of tremors and improve motor function in individuals with essential tremor.
Off-Label Uses: Primidone may be used off-label for the treatment of other medical conditions, including certain movement disorders such as Parkinson's disease, restless legs syndrome, and neuropathic pain. However, its efficacy for these indications may vary, and the use of primidone for off-label purposes should be carefully evaluated by a healthcare professional.
Adverse Effects: Common side effects of primidone may include drowsiness, dizziness, fatigue, nausea, vomiting, loss of appetite, and coordination difficulties. These side effects are usually mild and may improve over time as the body adjusts to the medication. However, some individuals may experience more serious side effects, such as allergic reactions, mood changes, memory problems, or liver dysfunction.
Drug Interactions: Primidone may interact with other medications, including other anticonvulsants, psychiatric medications, and certain antibiotics. It is important for healthcare providers to assess potential drug interactions and adjust dosages accordingly when prescribing primidone.
Monitoring: Individuals taking primidone may require regular monitoring of blood levels of the medication to ensure therapeutic efficacy and minimize the risk of side effects or toxicity. Blood tests may also be performed to monitor liver function and assess for any adverse effects on blood cell counts.
Pregnancy and Breastfeeding: Primidone should be used with caution during pregnancy, as it may pose risks to the developing fetus. Pregnant individuals taking primidone should be closely monitored by a healthcare provider. Additionally, primidone may be excreted in breast milk, so breastfeeding while taking primidone should be discussed with a healthcare provider.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
0 | 1 | Veillonella rodentium | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
0 | 1 | Bifidobacterium angulatum | species | Decreases |
0 | 1 | Veillonella dispar | species | Decreases |
0 | 1 | Bifidobacterium breve | species | Decreases |
0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Veillonella nakazawae | species | Decreases |
0 | 1 | Parolsenella catena | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
0 | 1 | Veillonella rogosae | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
Acne | 0.2 | -0.2 | |
ADHD | 1.4 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.2 | |
Allergic Rhinitis (Hay Fever) | 0.5 | 1.2 | -1.4 |
Allergies | 1.8 | 1.3 | 0.38 |
Allergy to milk products | 0.7 | 0.4 | 0.75 |
Alopecia (Hair Loss) | 0.3 | 0.3 | |
Alzheimer's disease | 1.3 | 1.7 | -0.31 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.4 | 1.75 |
Ankylosing spondylitis | 1.3 | 0.2 | 5.5 |
Anorexia Nervosa | 0.2 | 0.6 | -2 |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 1.6 | 1.5 | 0.07 |
Atherosclerosis | 0.6 | 0.7 | -0.17 |
Atrial fibrillation | 0.7 | 0.5 | 0.4 |
Autism | 2.2 | 2.7 | -0.23 |
Autoimmune Disease | 0.3 | 0.4 | -0.33 |
Barrett esophagus cancer | 0.2 | 0.2 | |
benign prostatic hyperplasia | 0.1 | 0.1 | 0 |
Biofilm | 0.3 | 0.3 | |
Bipolar Disorder | 0.2 | 0.4 | -1 |
Brain Trauma | 0.4 | 0.5 | -0.25 |
Breast Cancer | 0.1 | 0.1 | |
Cancer (General) | 0.4 | 1.9 | -3.75 |
Carcinoma | 0.9 | 0.8 | 0.13 |
Celiac Disease | 0.9 | 1.4 | -0.56 |
Cerebral Palsy | 0.6 | 0.3 | 1 |
Chronic Fatigue Syndrome | 1.5 | 1.3 | 0.15 |
Chronic Kidney Disease | 1 | 0.5 | 1 |
Chronic Lyme | 0 | 0.3 | 0 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.4 | -0.33 |
Chronic Urticaria (Hives) | 0.3 | 0.4 | -0.33 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.2 | 0 |
Cognitive Function | 0.6 | 0.6 | 0 |
Colorectal Cancer | 1.1 | 0.8 | 0.38 |
Constipation | 0.3 | 0.2 | 0.5 |
Coronary artery disease | 0.3 | 0.7 | -1.33 |
COVID-19 | 2.8 | 3.1 | -0.11 |
Crohn's Disease | 1.5 | 1.6 | -0.07 |
Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
cystic fibrosis | 0.2 | 0.9 | -3.5 |
d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
deep vein thrombosis | 0.3 | 0.3 | 0 |
Denture Wearers Oral Shifts | 0.4 | 0.4 | |
Depression | 3.7 | 3.4 | 0.09 |
Dermatomyositis | 0.2 | -0.2 | |
Eczema | 0.2 | 0.6 | -2 |
Endometriosis | 0.6 | 0.7 | -0.17 |
Eosinophilic Esophagitis | 0.2 | -0.2 | |
Epilepsy | 0.8 | 0.8 | 0 |
erectile dysfunction | 0.2 | 0.2 | 0 |
Fibromyalgia | 0.5 | 0.4 | 0.25 |
Functional constipation / chronic idiopathic constipation | 1.2 | 0.9 | 0.33 |
gallstone disease (gsd) | 0.5 | 0.5 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.3 | -0.5 |
Generalized anxiety disorder | 0.5 | 0.8 | -0.6 |
Gout | 1.2 | 0.1 | 11 |
Graves' disease | 0.7 | 1 | -0.43 |
Gulf War Syndrome | 0 | 0.7 | 0 |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 0.9 | 0.5 | 0.8 |
Heart Failure | 0.4 | 0.5 | -0.25 |
hemorrhagic stroke | 0.1 | 0.1 | |
Hidradenitis Suppurativa | 0.2 | 0.2 | 0 |
High Histamine/low DAO | 0.3 | 0.2 | 0.5 |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | 0 |
hyperglycemia | 0.6 | 0.8 | -0.33 |
Hyperlipidemia (High Blood Fats) | 0.5 | 0.2 | 1.5 |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 1.2 | 2.2 | -0.83 |
Hypothyroidism | 0.1 | 0.3 | -2 |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 0.2 | 1.2 | -5 |
Inflammatory Bowel Disease | 1.6 | 2.8 | -0.75 |
Insomnia | 0.4 | 1 | -1.5 |
Intelligence | 0.4 | 0.1 | 3 |
Intracranial aneurysms | 0.2 | 0.2 | 0 |
Irritable Bowel Syndrome | 2.4 | 1.4 | 0.71 |
ischemic stroke | 1 | 0.3 | 2.33 |
Liver Cirrhosis | 2 | 1.4 | 0.43 |
Long COVID | 1.9 | 2.6 | -0.37 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.4 | 0.4 | 0 |
Lymphoma | 0.1 | 0.1 | |
Mast Cell Issues / mastitis | 0.1 | 0.2 | -1 |
ME/CFS with IBS | 0.3 | 0.6 | -1 |
ME/CFS without IBS | 0.1 | 0.6 | -5 |
Menopause | 1 | 0.3 | 2.33 |
Metabolic Syndrome | 2 | 2.7 | -0.35 |
Mood Disorders | 4.1 | 3 | 0.37 |
multiple chemical sensitivity [MCS] | 0.3 | 0 | 0 |
Multiple Sclerosis | 1.7 | 1 | 0.7 |
Multiple system atrophy (MSA) | 0.7 | 0.2 | 2.5 |
myasthenia gravis | 0.1 | 0.2 | -1 |
neuropathic pain | 0 | 1.3 | 0 |
Neuropathy (all types) | 0.2 | 0.6 | -2 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 2.1 | -0.75 |
NonCeliac Gluten Sensitivity | 0.9 | 0.3 | 2 |
Obesity | 3.7 | 2.8 | 0.32 |
obsessive-compulsive disorder | 0.7 | 1.1 | -0.57 |
Osteoarthritis | 0.2 | 0.5 | -1.5 |
Osteoporosis | 0.6 | 0.7 | -0.17 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 2 | 1.6 | 0.25 |
Polycystic ovary syndrome | 0.7 | 0.9 | -0.29 |
Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
Premenstrual dysphoric disorder | 0.4 | 0.4 | |
primary biliary cholangitis | 0.3 | 0.2 | 0.5 |
Primary sclerosing cholangitis | 0.8 | 0.1 | 7 |
Psoriasis | 1.2 | 0.7 | 0.71 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 1.2 | 0.75 |
Rosacea | 0.2 | 0.2 | 0 |
Schizophrenia | 2.5 | 0.9 | 1.78 |
scoliosis | 0.1 | 0.1 | 0 |
Sjögren syndrome | 0.9 | 0.9 | 0 |
Sleep Apnea | 0.3 | 0.4 | -0.33 |
Slow gastric motility / Gastroparesis | 0.4 | 0.2 | 1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | 0 |
Stress / posttraumatic stress disorder | 0.8 | 1 | -0.25 |
Systemic Lupus Erythematosus | 0.6 | 1.2 | -1 |
Tic Disorder | 0.2 | 0.6 | -2 |
Tourette syndrome | 0.2 | 0.1 | 1 |
Type 1 Diabetes | 0.7 | 1.5 | -1.14 |
Type 2 Diabetes | 2.3 | 2.3 | 0 |
Ulcerative colitis | 1.2 | 1.6 | -0.33 |
Unhealthy Ageing | 0.8 | 0.7 | 0.14 |
Vitiligo | 0.4 | 0.3 | 0.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]